Media stories about MGC Diagnostics Corporation (NASDAQ:MGCD) have trended somewhat positive recently, according to Accern. The research group identifies negative and positive press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. MGC Diagnostics Corporation earned a media sentiment score of 0.02 on Accern’s scale. Accern also assigned news headlines about the medical equipment provider an impact score of 46.3324270243884 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

MGC Diagnostics Corporation (MGCD) traded up 0.000% during mid-day trading on Friday, hitting $8.617. 2,491 shares of the stock traded hands. MGC Diagnostics Corporation has a 12-month low of $6.24 and a 12-month high of $10.60. The firm’s 50-day moving average is $8.43 and its 200-day moving average is $8.24. The company’s market cap is $37.99 million.

MGC Diagnostics Corporation (NASDAQ:MGCD) last issued its quarterly earnings results on Wednesday, September 6th. The medical equipment provider reported $0.17 EPS for the quarter. The business had revenue of $10.41 million during the quarter. MGC Diagnostics Corporation had a negative net margin of 8.85% and a positive return on equity of 3.51%. Equities research analysts expect that MGC Diagnostics Corporation will post $0.06 EPS for the current year.

ILLEGAL ACTIVITY WARNING: This news story was originally posted by Watch List News and is owned by of Watch List News. If you are viewing this news story on another website, it was illegally stolen and republished in violation of US & international copyright & trademark legislation. The original version of this news story can be viewed at

About MGC Diagnostics Corporation

MGC Diagnostics Corporation is a medical technology company, which offers cardiorespiratory health solutions. The Company designs, markets and sells non-invasive cardiorespiratory diagnostic products. It sells its products internationally through distributors and in the United States through a direct sales force targeting specialists located in hospitals, university-based medical centers, medical clinics, physician offices, pharmaceutical companies, medical device manufacturers and clinical research organizations (CROs).

Insider Buying and Selling by Quarter for MGC Diagnostics Corporation (NASDAQ:MGCD)

Receive News & Ratings for MGC Diagnostics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MGC Diagnostics Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.